The European Patent Organization granted the patent for the Mycobacterial Cell Wall-DNA Complex (MCC), which comprises compositions with antiviral, immune adjuvant, and immune stimulatory activity, as well as chemotherapeutic activity against cancer cells.
A number of compositions are commercialized for use in veterinary applications, and the company is actively developing compositions for use in a number of human applications.
Graeme McRae, president & CEO of Bioniche, said: “The mycobacterial cell wall technology is the core of our product development pipeline. The latest formulation of the technology – MCC – is being targeted for the treatment of bladder cancer initially, with a phase III clinical trial planned in North America and Europe. We have already conducted a phase I clinical study for prostate cancer and plan to initiate further studies once the bladder cancer phase III trial is underway.”